Scios Says FDA Is Ready to Approve Its Heart Drug
Biotech firm Scios (SCIO) said late Tuesday that U.S. drug regulators will approve its heart failure drug, Natrecor, although the company still has some hoops to jump through before the drug can hit the market.
Scios COO Richard Brewer, speaking on an analyst conference call, said the company was working quickly to clear up the final steps and that the drug's approval was "imminent." Natrecor is expected to hit pharmacy shelves in the third quarter.
Natrecor's approval is a nice win for Scios, especially given the fact that the FDA has issued a
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts